Abstract
The glomerular endothelial glycocalyx (GEnGlx) forms the first part of the glomerular filtration barrier (GFB). We have previously shown that excess mineralocorticoid receptor (MR) activation causes GEnGlx damage and albuminuria. Damage to the GEnGlx occurs early in the pathogenesis of diabetic nephropathy (DN). Here we sought to determine whether MR antagonism with spironolactone could prevent the development of albuminuria in diabetes, by preserving the GEnGlx to maintain the GFB. Streptozotocin-induced diabetic Wistar rats developed increased glomerular albumin permeability (Ps’alb) and albuminuria, with associated GEnGlx loss and increases in plasma and urine active matrix metalloproteinase 2 (MMP2). MR antagonism reduced urine active MMP2, preserved the GEnGlx, restored Ps’alb to control values and prevented diabetes-induced albuminuria progression. Enzymatic degradation of the GEnGlx, with hyaluronidase, reversed the effect of MR antagonism in diabetic rats, confirming the importance of GEnGlx preservation in this model. Using this model we validated a novel fluorescent profile peak-to-peak confocal imaging technique and applied it to assess GEnGlx damage on renal biopsies from patients with DN and compared them to healthy controls. We confirmed that GEnGlx loss occurs in human DN and may contribute to the disease phenotype. Taken together our work suggests GEnGlx preservation as an important novel mechanism for reno-protection by MR inhibitors in diabetes.
Translational Statement Mineralocorticoid receptor (MR) antagonists reduce albuminuria in diabetic nephropathy (DN), but side effects limit their clinical utility, and the mechanism is unknown. This paper demonstrates that MR antagonism prevented the development of glomerular endothelial glycocalyx (GEnGlx) dysfunction and albuminuria. Highly specific, enzyme mediated, removal of the GEnGlx abolished this effect, confirming the importance of EnGlx preservation in this model. Our data also confirm that GEnGlx damage occurs in human DN and may contribute to the clinical phenotype. This work suggests directly targeting glycocalyx preservation in DN could reproduce the protective effects seen with MR inhibition, whilst avoiding side effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Sources of support: Kidney Research UK grants (RP_031_20180306, S/RP/2015/10, ID_004_20170330 and IN_004_20190305); a Diabetes UK grant (18/0005795); a British Heart Foundation grant (PG/15/81/31740 for K.L.O.); and a Medical Research Council Clinical Research Training Fellowship grant (MR/M018237/1 for M.J.B.). P.P., L.G. and S.C.S. are members of the Biomarker Enterprise to Attack Diabetic Kidney Disease (BEAt-DKD) consortium and as such this project has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI 2 JU) under grant agreement no. 115974. This Joint Undertaking receives support from the European Unions Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples provided in Bristol, samples were archived anonymised samples obtained following ethical review and approval by the NHS research ethics committee (NHS REC H0102/45). For samples obtained from Bari, the study was approved by the Independent Ethics Committee of the Azienda Ospedaliero Universitaria Policlinico Consorziale di Bari; all patients gave written informed consent for the use of this material for research purposes and the study was conducted in accordance with the Helsinki Declaration and patients gave written informed consent for the use of this material for research (Study no. 5156/2017).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Matthew J. Butler and Simon C. Satchell should be considered joint senior author
Sources of support: Kidney Research UK grants (RP_031_20180306, S/RP/2015/10, ID_004_20170330 and IN_004_20190305); a Diabetes UK grant (18/0005795); a British Heart Foundation grant (PG/15/81/31740 for K.L.O.); and a Medical Research Council Clinical Research Training Fellowship grant (MR/M018237/1 for M.J.B.). P.P., L.G. and S.C.S. are members of the Biomarker Enterprise to Attack Diabetic Kidney Disease (BEAt-DKD) consortium and as such this project has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI 2 JU) under grant agreement no. 115974. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations.
Data Availability
Non sensitive data will be made available to genuine researchers following publication of the original article
